AbbVie to create 300 new jobs with $380m Illinois manufacturing investment

AbbVie has announced a $380m investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago campus, expanding U.S. production capacity for next-generation medicines and creating around 300 new jobs.

The new facilities will support production of AbbVie’s future neuroscience and obesity treatments, integrating advanced manufacturing technologies and artificial intelligence into API production processes. Construction is scheduled to begin in spring 2026, with both plants expected to be operational by 2029.

AbbVie CEO Robert A. Michael said the project reflects the company’s long-term commitment to U.S. manufacturing.

“This milestone demonstrates further progress against our $100bn commitment to U.S. R&D and capital investments over the next decade,” he said. “By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients.”

API manufacturing involves producing the active components responsible for a drug’s therapeutic effects, a complex multi-step process often outsourced globally. AbbVie has spent the past six months outlining plans to expand API capacity in the United States.

In September 2025, the company broke ground on a chemical synthesis facility intended to bring production of selected neuroscience, immunology and oncology APIs back from Europe and Asia to the U.S.

The latest investment is expected to support approximately 300 new roles in North Chicago, including engineers, scientists, manufacturing operators and laboratory technicians.

AbbVie employs around 29,000 people across the United States, including more than 6,000 at its domestic manufacturing sites and over 11,500 in Illinois. The North Chicago expansion reinforces the company’s long-standing presence in the state, where it is headquartered.

The investment also forms part of a wider U.S. manufacturing push. AbbVie recently announced plans to acquire a device manufacturing facility in Arizona and expand operations in Massachusetts, and said it is in talks with several states about additional projects expected to be announced in 2026.

AbbVie’s move reflects a wider trend across North American pharmaceutical manufacturing, where companies are investing in domestic API production to improve supply-chain resilience, meet regulatory expectations, and take advantage of government incentives.

As demand rises for obesity and neuroscience treatments, increased U.S. API capacity could play a key role in ensuring reliable supply while accelerating the adoption of advanced manufacturing technologies.

Source link

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23 (Reuters) – AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its neuroscience and obesity medicines.

The investment is part of AbbVie’s broader effort to scale up domestic manufacturing, as drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory amid the Trump administration’s hefty tariffs on pharmaceutical imports into the country.

The U.S. government imposed a 100% tariff on branded drugs in October, but said it would only apply to producers who had not already broken ground on U.S. manufacturing plants.

AbbVie said the construction at the new facility in North Chicago, Illinois would begin in spring 2026, with both new facilities expected to be fully operational in 2029.

The new facilities will integrate advanced manufacturing technologies and artificial intelligence to support production of future pipeline medicines, the company said.

API production – the process of making a drug’s active chemical components – is one of the most complex steps in pharmaceutical manufacturing, the drugmaker said.

AbbVie said it plans to hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians.

In January, it committed $100 billion over the next decade to U.S.-based research and development, including an earlier $195 million expansion at the same North Chicago site to boost API production for immunology, oncology and neuroscience drugs.

AbbVie already has 11 manufacturing sites in the U.S. and is also in discussions with multiple U.S. states about potential projects and expects to announce further investments in 2026.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by Maju Samuel)

Source link

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

• Milestone marks progress against AbbVie‘s previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade to broadly support innovation and expand critical manufacturing capabilities and capacity
• Supports production of AbbVie‘s current and next-generation immunology and neuroscience medicines
• Transaction anticipated to close in mid-2026

AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West. The acquisition of the manufacturing site will significantly expand AbbVie‘s drug delivery device manufacturing capabilities and capacity.

AbbVie plans to hire approximately 200 employees at the site and invest more than $175 million to acquire, as well as modernize and fully integrate it into its global manufacturing network. The combination of this acquisition and associated planned investments are part of AbbVie‘s commitment to expanding its pharmaceutical manufacturing in the United States (U.S.), supporting innovation and improving patient access and outcomes.

“Over the next decade, AbbVie is investing more than $10 billion in capital to broadly support innovation and expand our manufacturing capabilities and capacity in the U.S.,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “With this investment, AbbVie is strengthening our manufacturing capabilities, ensuring we are well-positioned to develop and deliver next-generation medicines that make a remarkable impact on patients’ lives.”

The transaction includes the transfer of manufacturing facilities, including multiple production lines, and 3.5 mL on-body injector technology to support production of current and next-generation AbbVie immunology and neuroscience medicines.

With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the U.S., including more than 6,000 at its 11 U.S. manufacturing sites. When completed, this acquisition will significantly expand AbbVie‘s presence and economic impact in Arizona.

The transaction is anticipated to close in mid-2026, subject to closing conditions.

About AbbVie 

AbbVie‘s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube. 

Forward-Looking Statements  

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie‘s operations is set forth in Item 1A, “Risk Factors,” of AbbVie‘s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

View original content:https://www.prnewswire.com/news-releases/abbvie-to-acquire-arizona-manufacturing-facility-further-strengthening-manufacturing-capabilities-in-the-united-states-302658118.html

SOURCE AbbVie

Source link